Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction

• DOI: 10.3904/kjim.2023.065
• Publication Date: 2023-08-30T23:34:46Z
• Authors: Su Yeong Park; Min Gyu Kong; Inki Moon; Hyun Woo Park; Hyung-Oh Choi; Hye Sun Seo; Yoon Haeng Cho; Nae-Hee Lee; Kwan Yong Lee; Ho-Jun Jang; Je Sang Kim; Ik Jun Choi; Jon Suh
• Keywords: Discontinuation

Background/Aims: We aimed to analyze the efficacy of angiotensin receptor-neprilysin inhibitor (ARNI) by disease course heart failure (HF).Methods: evaluated 227 patients with HF in a multi-center retrospective cohort that included those left ventricular ejection fraction (LVEF) ≤ 40% undergoing ARNI treatment. The were divided into newly diagnosed treatment initiated within 6 months diagnosis (de novo group) and who or admitted for exacerbation more than prior initiation (prior group). primary outcome was composite cardiovascular death worsening HF, including hospitalization an emergency visit aggravation 12 months.Results: No significant differences baseline characteristics reported between de groups. group significantly associated higher (23.9 vs. 9.4%) (adjusted hazard ratio 2.52, 95% confidence interval 1.06–5.96, p = 0.036), although on initial dose. showed better LVEF improvement after 1 year (12.0% vs 7.4%, 0.010). Further, discontinuation rate diuretics numerically (34.4 18.5%, 0.064).Conclusions: had lower risk reduced treated ARNI.